There are 2789 resources available
418P - Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Presenter: Manuel Benavides
Session: ePoster Display
419P - XELOX/XELIRI alternative regimen as first-line treatment of metastatic colorectal cancer (CCRCTO-2: TROT): A phase II study
Presenter: YU HAN
Session: ePoster Display
420P - A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)
Presenter: Kefeng Ding
Session: ePoster Display
421P - FOLFIRINOX with or without targeted therapy as first line for metastatic colorectal cancer: An AGEO multicenter real-world study
Presenter: Romain Varnier
Session: ePoster Display
422P - The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: A summary analysis of a multicenter, phase II trial
Presenter: Xiujuan Qu
Session: ePoster Display
423P - From clinical trial to bedside: Triplet chemotherapy (FOLFOXIRI-B) in metastatic colorectal cancer
Presenter: Guus Bol
Session: ePoster Display
307P - Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer
Presenter: Eva Blondeaux
Session: ePoster Display
308P - FDG-PET/CT versus CE-CT for response monitoring in metastatic breast cancer: A prospective comparative study
Presenter: Marianne Vogsen
Session: ePoster Display
309P - Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
Presenter: Fabrice André
Session: ePoster Display
310P - Substantial reduction in the percentage of metastatic breast cancer (MBC) which is HER-2 positive (HER-2+) over two decades: Sequential cohort analysis from the 1000 patient HER-2 study
Presenter: Jose Javier Berenguer-pina
Session: ePoster Display